Bivalent COVID-19 mRNA booster vaccination (BA.1 or BA.4/BA.5) increases neutralization of matched Omicron variants

被引：0
|
作者：
David N. Springer
Michael Bauer
Iris Medits
Jeremy V. Camp
Stephan W. Aberle
Clemens Burtscher
Eva Höltl
Lukas Weseslindtner
Karin Stiasny
Judith H. Aberle
机构：
[1] Medical University of Vienna,Center for Virology
[2] Erste Bank,Health Center Erste Bank
[3] Medical University of Vienna,Center for Public Health
来源：
npj Vaccines | / 8卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
We report SARS-CoV-2 neutralizing antibody titers in sera of triple-vaccinated individuals who received a booster dose of an original monovalent or a bivalent BA.1- or BA.4/BA.5-adapted vaccine or had a breakthrough infection with Omicron variants BA.1, BA.2 or BA.4/BA.5. A bivalent BA.4/BA.5 booster or Omicron-breakthrough infection induced increased Omicron-neutralization titers compared with the monovalent booster. The XBB.1.5 variant effectively evaded neutralizing-antibody responses elicited by current vaccines and/or infection with previous variants.
引用
收藏
相关论文
共 50 条
  • [41] Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1 infection (vol 608, pg 593, 2022)
    Khan, Khadija
    Karim, Farina
    Ganga, Yashica
    Bernstein, Mallory
    Jule, Zesuliwe
    Reedoy, Kajal
    Cele, Sandile
    Lustig, Gila
    Amoako, Daniel
    Wolter, Nicole
    Samsunder, Natasha
    Sivro, Aida
    San, James Emmanuel
    Giandhari, Jennifer
    Tegally, Houriiyah
    Pillay, Sureshnee
    Naidoo, Yeshnee
    Mazibuko, Matilda
    Miya, Yoliswa
    Ngcobo, Nokuthula
    Manickchund, Nithendra
    Magula, Nombulelo
    Karim, Quarraisha Abdool
    von Gottberg, Anne
    Abdool Karim, Salim S.
    Hanekom, Willem
    Gosnell, Bernadett I.
    Lessells, Richard J.
    de Oliveira, Tulio
    Moosa, Mahomed-Yunus S.
    Sigal, Alex
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [42] Effectiveness of the COVID-19 vaccines against hospitalisation with Omicron sub-lineages BA.4 and BA.5 in England
    Kirsebom, Freja Cordelia Moller
    Andrews, Nick
    Stowe, Julia
    Groves, Natalie
    Chand, Meera
    Ramsay, Mary
    Bernal, Jamie Lopez
    LANCET REGIONAL HEALTH-EUROPE, 2022, 23
  • [43] Persistent Laplacian projected Omicron BA.4 and BA.5 to become new dominating variants
    Chen, Jiahui
    Qiu, Yuchi
    Wang, Rui
    Wei, Guo-Wei
    Computers in Biology and Medicine, 2022, 151
  • [44] Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages
    Ackerson, Bradley K.
    Bruxvoort, Katia J.
    Qian, Lei
    Sy, Lina S.
    Qiu, Sijia
    Tubert, Julia E.
    Lee, Gina S.
    Ku, Jennifer H.
    Florea, Ana
    Luo, Yi
    Bathala, Radha
    Stern, Julie
    Choi, Soon K.
    Takhar, Harpreet S.
    Aragones, Michael
    Marks, Morgan A.
    Anderson, Evan J.
    Zhou, Cindy Ke
    Sun, Tianyu
    Talarico, Carla A.
    Tseng, Hung Fu
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [45] BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
    Roessler, Annika
    Netzl, Antonia
    Knabl, Ludwig
    Schaefer, Helena
    Wilks, Samuel H.
    Bante, David
    Falkensammer, Barbara
    Borena, Wegene
    von Laer, Dorothee
    Smith, Derek J.
    Kimpel, Janine
    NATURE COMMUNICATIONS, 2022, 13 (01)
  • [46] Immunogenicity and durability against Omicron BA.1, BA.2 and BA.4/5 variants at 3-4 months after a heterologous COVID-19 booster vaccine in healthy adults with a two-doses CoronaVac vaccination
    Assawakosri, Suvichada
    Kanokudom, Sitthichai
    Suntronwong, Nungruthai
    Chansaenroj, Jira
    Auphimai, Chompoonut
    Nilyanimit, Pornjarim
    Vichaiwattana, Preeyaporn
    Thongmee, Thanunrat
    Duangchinda, Thaneeya
    Chantima, Warangkana
    Pakchotanon, Pattarakul
    Srimuan, Donchida
    Thatsanathorn, Thaksaporn
    Klinfueng, Sirapa
    Sudhinaraset, Natthinee
    Wanlapakorn, Nasamon
    Mongkolsapaya, Juthathip
    Honsawek, Sittisak
    Poovorawan, Yong
    HELIYON, 2024, 10 (01)
  • [47] BA.2 and BA.5 omicron differ immunologically from both BA.1 omicron and pre-omicron variants
    Annika Rössler
    Antonia Netzl
    Ludwig Knabl
    Helena Schäfer
    Samuel H. Wilks
    David Bante
    Barbara Falkensammer
    Wegene Borena
    Dorothee von Laer
    Derek J. Smith
    Janine Kimpel
    Nature Communications, 13
  • [48] Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5
    Diem, Gabriel
    Jaeger, Michael
    Dichtl, Stefanie
    Bauer, Angelika
    Lass-Floerl, Cornelia
    Reindl, Markus
    Wilflingseder, Doris
    Posch, Wilfried
    MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [49] Antibody responses in blood and saliva post COVID-19 bivalent booster do not reveal an Omicron BA.4/BA.5-specific response
    Baker Jr, Ryan
    Lawlor, Rebecca
    Smith, Maeve
    Price, Jessica
    Eaton, Ashley
    Lover, Andrew
    Alfandari, Dominique
    Reinhart, Peter
    Arcaro, Kathleen F.
    Osborne, Barbara A.
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [50] Original SARS-CoV-2 monovalent and Omicron BA.4/BA.5 bivalent COVID-19 mRNA vaccines: phase 2/3 trial interim results
    Chalkias, Spyros
    Whatley, Jordan L.
    Eder, Frank
    Essink, Brandon
    Khetan, Shishir
    Bradley, Paul
    Brosz, Adam
    Mcghee, Nichole
    Tomassini, Joanne E.
    Chen, Xing
    Zhao, Xiaoping
    Sutherland, Andrea
    Shen, Xiaoying
    Girard, Bethany
    Edwards, Darin K.
    Feng, Jing
    Zhou, Honghong
    Walsh, Stephen
    Montefiori, David C.
    Baden, Lindsey R.
    Miller, Jacqueline M.
    Das, Rituparna
    NATURE MEDICINE, 2023, 29 (9) : 2325 - 2333
12345